BofA raised the firm’s price target on Merus (MRUS) to $92 from $70 and keeps a Buy rating on the shares after the company reported 12-month landmark objective survival of 79% in its full phase 2 cohort for petosemtamab plus pembrolizumab. This OS rate compares favorably to the historical 50%-59% benchmark for pembro monotherapy in first-line head and neck squamous cell carcinoma and is also significantly higher than the 50%-60% range the firm’s doctor checks had indicated would be “good data,” the analyst tells investors. The firm thinks the data sets the “peto’+pembro” combination up to be “the best-in-class treatment option for this patient population,” the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Promising Potential of Merus’s Petosemtamab: A Buy Rating Backed by Impressive Efficacy and Safety
- Merus’s Peto+Pembro Shows Promising Potential in HNSCC with High Survival Rates and Increased Price Target
- Merus’s Promising Oncology Advancements Justify Buy Rating Amidst Strong Clinical Results
- Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
- Merus updates on Petosemtamab+Pembrolizumab data in HNSCC
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue